{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "USD", "regularMarketChangePercent": -3.8823571, "regularMarketPrice": 0.0817, "exchange": "PNK", "shortName": "IMUGENE LIMITED", "longName": "Imugene Limited", "messageBoardId": "finmb_11113368", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "firstTradeDateMilliseconds": 1562333400000, "tradeable": false, "cryptoTradeable": false, "priceHint": 4, "regularMarketChange": -0.0033000037, "regularMarketTime": 1684161107, "regularMarketDayHigh": 0.0824, "regularMarketDayRange": "0.081 - 0.0824", "regularMarketDayLow": 0.081, "regularMarketVolume": 27217, "regularMarketPreviousClose": 0.085, "fullExchangeName": "Other OTC", "financialCurrency": "AUD", "regularMarketOpen": 0.081, "averageDailyVolume3Month": 120580, "averageDailyVolume10Day": 47171, "fiftyTwoWeekLowChange": 0.001699999, "fiftyTwoWeekLowChangePercent": 0.021249987, "fiftyTwoWeekRange": "0.08 - 0.2126", "fiftyTwoWeekHighChange": -0.1309, "fiftyTwoWeekHighChangePercent": -0.61571026, "fiftyTwoWeekLow": 0.08, "fiftyTwoWeekHigh": 0.2126, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.0, "sharesOutstanding": 6423040000, "bookValue": 0.032, "fiftyDayAverage": 0.0900492, "fiftyDayAverageChange": -0.008349203, "fiftyDayAverageChangePercent": -0.09271823, "twoHundredDayAverage": 0.12026845, "twoHundredDayAverageChange": -0.038568452, "twoHundredDayAverageChangePercent": -0.32068637, "marketCap": 524762336, "priceToBook": 2.553125, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "displayName": "Imugene", "symbol": "IUGNF"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "4-6 Bligh Street", "address2": "Suite 12.01 Level 12", "city": "Sydney", "state": "NSW", "zip": "2000", "country": "Australia", "website": "https://www.imugene.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD", "age": 66, "title": "Exec. Chairman", "yearBorn": 1956, "fiscalYear": 2022, "totalPay": {"raw": 232610, "fmt": "232.61k", "longFmt": "232,610"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Leslie  Chong", "title": "CEO, MD & Exec. Director", "fiscalYear": 2022, "totalPay": {"raw": 708592, "fmt": "708.59k", "longFmt": "708,592"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2022, "totalPay": {"raw": 281110, "fmt": "281.11k", "longFmt": "281,110"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Monil  Shah M.B.A., Pharm.D.", "title": "Chief Bus. Officer", "fiscalYear": 2022, "totalPay": {"raw": 546129, "fmt": "546.13k", "longFmt": "546,129"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Michael  Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD", "age": 55, "title": "CFO & Company Sec.", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Ursula  McCurry", "title": "Sr. VP of Clinical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Giovanni  Selvaggi", "title": "Chief Medical Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 8, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 1, "overallRisk": 10, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}